Advertisement

Topics

FDA Approves Triptodur for Treatment of Central Precocious Puberty

06:30 EDT 3 Jul 2017 | PharmPro

Arbor Pharmaceuticals, LLC and Debiopharm International SA announce U.S. FDA approval for Triptodur, Triptorelin 6-month formulation, in the treatment of central precocious puberty (CPP). It's the first such treatment approval for U.S. children in six years.
Contributed Author: 
Arbor Pharmaceuticals LLC

Original Article: FDA Approves Triptodur for Treatment of Central Precocious Puberty

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Triptodur for Treatment of Central Precocious Puberty"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...